Literature DB >> 9825790

Maternal antibody to hepatitis B core antigen detected in dried neonatal blood spot samples.

D M Tappin1, K Greer, S Cameron, R Kennedy, A J Brown, R W Girdwood.   

Abstract

Despite Department of Health recommendations, universal antenatal testing for hepatitis B virus (HBV) is not performed throughout Scotland. We describe the evaluation of an assay to document past or present infection with HBV, by identifying maternal antibody in routine Guthrie dried neonatal blood spot samples taken when infants are 7 days old. A modified haemagglutination assay to detect antibody to hepatitis B core antigen (CORECELL, Green Cross) was validated and found to be 79% sensitive (44/56) and 100% (105/105) specific when used with dried blood spot samples made from panels of serum of known reactivity. Ninety-three percent (13/14) of HBV carriers were CORECELL positive. Sixty-six (0.5%) of 14044 routine Guthrie samples taken from babies born in Scotland from June August 1992 were CORECELL positive indicating past or present maternal infection with HBV. A cross-sectional survey would document the maternity hospitals where universal antenatal hepatitis B screening should be urgently established.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9825790      PMCID: PMC2809536          DOI: 10.1017/s0950268898001393

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  9 in total

Review 1.  Innovations in health and demographic surveillance systems to establish the causal impacts of HIV policies.

Authors:  Kobus Herbst; Matthew Law; Pascal Geldsetzer; Frank Tanser; Guy Harling; Till Bärnighausen
Journal:  Curr Opin HIV AIDS       Date:  2015-11       Impact factor: 4.283

Review 2.  What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research.

Authors:  Thomas W McDade; Sharon Williams; J Josh Snodgrass
Journal:  Demography       Date:  2007-11

3.  Feasibility of freeze-dried sera for serological and molecular biological detection of hepatitis B and C viruses.

Authors:  Waka Ohishi; Saeko Fujiwara; Gen Suzuki; Takeshi Kishi; Misae Sora; Shinsuke Matsuura; Masayuki Hakoda; Yoshimi Tatsukawa; Michiko Yamada; Kazuaki Chayama
Journal:  J Clin Microbiol       Date:  2006-10-11       Impact factor: 5.948

4.  Hepatitis B assays in serum, plasma and whole blood on filter paper.

Authors:  Theodor K Mayer; Roberto L Vargas; Ann E Knebel; Scott A Williams; Sean P Culver; Daniel M Clark; Louise R King
Journal:  BMC Clin Pathol       Date:  2012-05-20

5.  Hepatitis B in pregnancy.

Authors:  Jessica Katharine Dyson; Julia Waller; Andrena Turley; Enid Michael; Samuel Moses; Manoj Valappil; Mark Hudson; Margaret Bassendine; Stuart McPherson
Journal:  Frontline Gastroenterol       Date:  2013-10-17

6.  Dried blood spot is the feasible matrix for detection of some but not all hepatitis B virus markers of infection.

Authors:  Minami Kikuchi; Patrick Lindstrom; Alexandra Tejada-Strop; Tonya Mixson-Hayden; Saleem Kamili; Motoji Sawabe
Journal:  BMC Res Notes       Date:  2022-09-05

7.  Use of dried blood samples for monitoring hepatitis B virus infection.

Authors:  Rosalia Lira; Angelica Maldonado-Rodriguez; Othon Rojas-Montes; Martha Ruiz-Tachiquin; Rocio Torres-Ibarra; Carlos Cano-Dominguez; Hilda Valdez-Salazar; Alejandro Gomez-Delgado; Onofre Muñoz; Ma-Teresa Alvarez-Muñoz
Journal:  Virol J       Date:  2009-09-29       Impact factor: 4.099

8.  Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots--performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification.

Authors:  R Stefan Ross; Oumaima Stambouli; Nico Grüner; Ulrich Marcus; Wei Cai; Weidong Zhang; Ruth Zimmermann; Michael Roggendorf
Journal:  Virol J       Date:  2013-03-05       Impact factor: 4.099

9.  Dried blood spot sampling for hepatitis B virus serology and molecular testing.

Authors:  Sofiane Mohamed; Audrey Raimondo; Guillaume Pénaranda; Claire Camus; Denis Ouzan; Sophie Ravet; Marc Bourlière; Hacène Khiri; Patrick Dukan; Daniel Olive; Philippe Halfon
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.